

Day : Wednesday
Date: 8/4/2004
Time: 15:13:54



Inventor Name Search Result

Your Search was:

Last Name = DAVIS
First Name = PETER

Application#	Patent#	Status	Date Filed	Title	Inventor Name 51
60528655	Not Issued	020	12/11/2003	HAND HELD VIDEO LOTTERY GAME	DAVIS, PETER LORNE
60507473	Not Issued	020	09/30/2003	OTOSCOPIC INSTRUMENT SYSTEM	DAVIS, PETER J.
60499007	Not Issued	020	09/02/2003	X-RAY EMITTER CATHETER AND METHOD OF TREATMENT USING SAME	DAVIS, PETER
60458659	Not Issued	020	03/28/2003	INTERFACE DEVICE WITH A RELEASABLE MOUNT THEREIN	DAVIS, PETER
60457501	Not Issued	020	03/24/2003	EDUCATION CERTIFICATE BUSINESS CASE	DAVIS, PETER
60423233	Not Issued	159	10/31/2002	APPARATUS FOR SELECTING AN INPUT MODE ON A MOBILE DEVICE	DAVIS, PETER
60410372	Not Issued	159	09/13/2002	METHOD AND APPARATUS TO EXTRACT A DIE FROM A WAFER WITH THE USE OF AN INCLINED PLANE	DAVIS, PETER
60394501	Not Issued	159	07/09/2002	LOW COST DIAGNOSTIC INSTRUMENTS	DAVIS, PETER J.
60387718	Not Issued	159	06/11/2002	SPILLAGE APRON	DAVIS, PETER M.
60369280	Not Issued	159	04/02/2002	METHODS AND APPARATUS FOR OPERATING A VIRTUAL PRIVATE NETWORK	DAVIS, PETER
60335969	Not Issued	159	10/19/2001	CONTENT INDEPENDENT DOCUMENT NAVIGATION	DAVIS, PETER W.
60318215	Not Issued	159	09/07/2001	OCCLUSION CATHETER HAVING COMPLIANT BALLOON FOR USE WITH COMPLEX VASCULATURE	DAVIS, PETER GREGORY
60317232	Not	159	09/04/2001	OCCLUSION CATHETER HAVING	DAVIS,

	Issued			COMPLIANT BALLON FOR USE WITH COMPLEX VASCULATURE	PETER GREGORY
<u>60308551</u>	Not Issued	159	07/27/2001	VOICE APPLICATION SERVER	DAVIS, PETER WILLIAM
<u>60291740</u>	Not Issued	159	05/17/2001	REWARD REDEMPTION SYSTEM AND METHOD	DAVIS, PETER
<u>60249501</u>	Not Issued	159	11/17/2000	WIRELESS COUPON-DISPENSING DEVICE	DAVIS, PETER
<u>60216855</u>	Not Issued	159	07/07/2000	WAFER INTERCHANGE GANTRY	DAVIS, PETER
<u>10810292</u>	Not Issued	020	03/26/2004	INTERFACE DEVICE WITH A RELEASABLE MOUNT	DAVIS, PETER
<u>10808107</u>	Not Issued	030	03/24/2004	SYSTEMS AND METHODS FOR PROMOTING SAVINGS THROUGH A COMPUTER-ENABLED CERTIFICATE PROGRAM	DAVIS, PETER
<u>10722619</u>	Not Issued	071	11/26/2003	SURFACE MOUNT ASSEMBLY SYSTEM WITH INTEGRAL LABEL FEEDER	DAVIS, PETER
<u>10612163</u>	Not Issued	030	07/03/2003	BENZIMIDAZOLE VASCULAR DAMAGING AGENTS	DAVIS, PETER DAVID
<u>10425787</u>	Not Issued	030	04/29/2003	METHODS AND APPARATUS FOR MAINTAINING A VIRTUAL PRIVATE NETWORK CONNECTION	DAVIS, PETER SCOTT
<u>10401433</u>	Not Issued	030	03/28/2003	INPUT MODE SELECTOR ON A MOBILE DEVICE	DAVIS, PETER GREGORY
<u>10393340</u>	Not Issued	030	03/20/2003	ILLUMINATION SYSTEM FOR MEDICAL DIAGNOSTIC INSTRUMENT	DAVIS, PETER J.
<u>10393319</u>	Not Issued	030	03/20/2003	ELECTRICAL ADAPTER FOR MEDICAL DIAGNOSTIC INSTRUMENTS USING LEDS AS ILLUMINATION SOURCES	DAVIS, PETER J.
<u>10367606</u>	Not Issued	041	02/14/2003	COMPOSITIONS WITH VASCULAR DAMAGING ACTIVITY	DAVIS, PETER DAVID
<u>10282816</u>	Not Issued	030	10/29/2002	METHOD AND APPARATUS FOR LOAD BALANCING IN A VIRTUAL PRIVATE NETWORK	DAVIS, PETER SCOTT
<u>10282503</u>	Not Issued	030	10/29/2002	METHOD AND APPARATUS PROVIDING VIRTUAL PRIVATE NETWORK ACCESS	DAVIS, PETER

<u>10278763</u>	Not Issued	030	10/21/2002	CONTENT INDEPENDENT DOCUMENT NAVIGATION SYSTEM AND METHOD	DAVIS, PETER W.
<u>10240213</u>	Not Issued	071	04/04/2003	N-ACETYLCOLCHINOL-O-PHOSPHATE COMBINATION THERAPIES WITH VASCULAR DAMAGING ACTIVITY	DAVIS, PETER DAVID
<u>10239941</u>	Not Issued	030	02/04/2003	BICYCLIC AMINE DERIVATIVES AS INHIBITORS OF CLASS 1 RECEPTOR TYROSINE KINASES	DAVIS, PETER DAVID
<u>10239898</u>	Not Issued	030	09/26/2002	DIVIDED DOSE THERAPIES WITH VASCULAR DAMAGING ACTIVITY	DAVIS, PETER DAVID
<u>10235064</u>	Not Issued	030	09/04/2002	OCCCLUSION CATHETER HAVING COMPLIANT BALLOON FOR USE WITH COMPLEX VASCULATURE	DAVIS, PETER GREGORY
<u>10162365</u>	Not Issued	030	06/03/2002	MONOMERIC DIOLS, PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM AND PROCESSES FOR PREPARING	DAVIS, PETER W.
<u>10154560</u>	Not Issued	071	05/24/2002	AUTO-LOADING COMPONENT TAPE FEEDER	DAVIS, PETER M.
<u>10136480</u>	Not Issued	030	05/01/2002	METHODS AND APPARATUS FOR USER AUTHENTICATION AND INTERACTIVE UNIT AUTHENTICATION	DAVIS, PETER
<u>10049248</u>	Not Issued	061	05/06/2002	STILBENES WITH VASCULAR DAMAGING ACTIVITY	DAVIS, PETER D.
<u>10018826</u>	Not Issued	030	04/22/2002	CHIMERIC PROTEINS MEDIATING TARGETED APOPTOSIS	DAVIS, PETER D.
<u>09992579</u>	Not Issued	041	11/16/2001	PERSONAL PRICING SYSTEM	DAVIS, PETER
<u>09897276</u>	Not Issued	161	07/02/2001	COMPONENT SOURCE INTERCHANGE GANTRY	DAVIS, PETER
<u>09890990</u>	Not Issued	071	10/22/2001	SUBSTITUTED STILBENE COMPOUNDS WITH VASCULAR DAMAGING ACTIVITY	DAVIS, PETER DAVID
<u>09890989</u>	Not Issued	061	12/14/2001	COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING ANGIOGENESIS	DAVIS, PETER DAVID
<u>09889061</u>	6645950	150	10/22/2001	BENZIMIDAZOLE VASCULAR DAMAGING AGENTS	DAVIS, PETER DAVID
<u>09869925</u>	Not Issued	041	08/14/2001	COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS	DAVIS, PETER D

<u>09863158</u>	Not Issued	071	05/23/2001	CHEMICAL SYNTHESIS APPARATUS EMPLOYING A DROPLET GENERATOR	DAVIS, PETER W.
<u>09787009</u>	<u>6489873</u>	150	06/12/2001	TEMPERATURE CONTROL SYSTEM FOR A PERMANENT MAGNETIC SYSTEM	DAVIS, PETER JONATHAN
<u>09747871</u>	Not Issued	041	12/22/2000	METHOD AND APPARATUS FOR END-TO-END CONTENT PUBLISHING SYSTEM USING XML WITH AN OBJECT DEPENDENCY GRAPH	DAVIS, PETER E.
<u>09731925</u>	Not Issued	094	12/08/2000	APPARATUS AND METHOD FOR TREATMENT OF MALIGNANT TUMORS	DAVIS, PETER G.
<u>09684189</u>	<u>6554128</u>	150	10/06/2000	DIE SHUTTLE CONVEYOR AND NEST THEREFOR	DAVIS, PETER
<u>09550030</u>	Not Issued	164	04/14/2000	SURFACE MOUNT ASSEMBLY SYSTEM WITH INTEGRAL LABEL FEEDER	DAVIS, PETER
<u>09517601</u>	<u>6599908</u>	150	03/02/2000	FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES	DAVIS, PETER DAVID

[Search and Display More Records.](#)

**Search Another:
Inventor**

Last Name

Davis

First Name

Peter

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

09/890,990

STN-STRUCTURE SEARCH
8-4-04

=> d ibib abs hitstr 1-3

Inventory
L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:896045 CAPLUS
DOCUMENT NUMBER: 139:374359
TITLE: Enhancement of vascular targeting by inhibitors of
nitric oxide synthase
AUTHOR(S): Davis, Peter D.; Tozer, Gillian M.; Naylor, Matthew
A.; Thomson, Peter; Lewis, Gemma; Hill, Sally A.
CORPORATE SOURCE: Angiogene Pharmaceuticals Ltd., Oxford, OX4 4GA, UK
SOURCE: ~~International Journal of Radiation Oncology, Biology,~~
~~Physics (2002), 54(5), 1532-1536~~
CODEN: ~~IOBPD3~~, ISSN: 0360-3016
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Purpose: This study investigates the enhancement of the vascular targeting activity of the tubulin-binding agent combretastatin A4 phosphate (CA4P) by various inhibitors of nitric oxide synthases. Methods and Materials: The syngeneic tumors CaNT and SaS growing in CBA mice were used for this study. Reduction in perfused vascular volume was measured by injection of Hoechst 33342 24 h after drug administration. Necrosis (hematoxylin and eosin stain) was assessed also at 24 h after treatment. Combretastatin A4 phosphate was synthesized by a modification of the published procedure and the **nitric oxide synthase inhibitors**

L-NNA, L-NMMA, L-NIO, L-NIL, S-MTC, S-EIT, AMP, AMT, and L-TC, obtained from com. sources. Results: A statistically significant augmentation of the reduction in perfused vascular volume by CA4P in the CaNT tumor was observed

with L-NNA, AMP, and AMT. An increase in CA4P-induced necrosis in the same tumor achieved significance with L-NNA, L-NMMA, L-NIL, and AMT. CA4P induced little necrosis in the SaS tumor, but combination with the inhibitors L-NNA, L-NMMA, L-NIO, S-EIT, and L-TC was effective.

Conclusions: Augmentation of CA4P activity by **nitric**

oxide synthase inhibitors of different

structural classes supports a nitric oxide-related mechanism for this effect. L-NNA was the most effective inhibitor studied.

IT 222030-63-9, Combretastatin A4 phosphate


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(enhancement of combretastatin A4 phosphate tumor vascular targeting by inhibitors of nitric oxide synthase)

RN 222030-63-9 CAPLUS

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Inventory
L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

09/890,990

ACCESSION NUMBER: 2000:592548 CAPLUS
DOCUMENT NUMBER: 133:177486
TITLE: Preparation of substituted stilbene compounds with
vascular damaging activity
INVENTOR(S): Davis, Peter David
PATENT ASSIGNEE(S): Angiogene Pharmaceuticals Ltd., UK
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048590	A1	20000824	WO 2000-GB503	20000215
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1154767	A1	20011121	EP 2000-903824	20000215
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002537250	T2	20021105	JP 2000-599382	20000215
PRIORITY APPLN. INFO.:			GB 1999-3403	A 19990216
			WO 2000-GB503	W 20000215

OTHER SOURCE(S): MARPAT 133:177486

AB A vascular damaging agent AXB (A = substituted cis-stilbene; X = linker bond, atom, or group; B = moiety derived from an inhibitor of the formation or action of NO in mammalian systems), is claimed. Thus, (Z)-1-[3-(N- α -tert-butoxycarbonyl-N- ω -nitroarginyloxy)-4-methoxyphenyl]-2-(3,4,5-trimethoxyphenyl)ethene was stirred with CF₃CO₂H in CH₂Cl₂ to give (Z)-1-(4-methoxy-3-NG-nitroarginyloxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene. The latter at 50 mg/kg i.p. in mice bearing CaNT or SaS tumors gave 95% reduction in vascular volume and 91-100% tumor necrosis.

IT **288585-54-6P 288585-55-7P 288585-56-8P**

288585-57-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted stilbene compds. with vascular damaging activity)


RN 288585-54-6 CAPLUS

CN L-Ornithine, N5-[imino(nitroamino)methyl]-, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


09/890,990



RN 288585-55-7 CAPLUS

CN L-Ornithine, N5-[imino(nitroamino)methyl]-N2-[[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxy]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 288585-56-8 CAPLUS

CN L-Ornithine, N5-[imino(nitroamino)methyl]-N2-[[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxy]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 288585-57-9 CAPLUS

CN L-Ornithine, N5-[imino(nitroamino)methyl]-N2-[[2-methyl-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxy]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

09/890,990



IT 117048-59-6 288585-58-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted stilbene compds. with vascular damaging activity)

RN 117048-59-6 CAPLUS

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 288585-58-0 CAPLUS

CN L-Ornithine, N2-[(1,1-dimethylethoxy)carbonyl]-N5-[imino(nitroamino)methyl]-, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 288585-59-1P 288585-60-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted stilbene compds. with vascular damaging activity)

09/890,990


RN 288585-59-1 CAPLUS
CN Phenol, 2-methyl-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 288585-60-4 CAPLUS
CN Silane, (1,1-dimethylethyl)dimethyl[2-methyl-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:241795 CAPLUS

DOCUMENT NUMBER: 131:39356

TITLE: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues

AUTHOR(S): Tozer, Gillian M.; Prise, Vivien E.; Wilson, John; Locke, Rosalind J.; Vojnovic, Borivoj; Stratford, Michael R. L.; Dennis, Madeleine F.; Chaplin, David J.

CORPORATE SOURCE: Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, HA6 2JR, UK

SOURCE: Cancer Research (1999), 59(7), 1626-1634

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: AACR Subscription Office

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-O-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established tumor vasculature, leading to the development of extensive tumor cell necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22 carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled iodoantipyrine, and quant. autoradiog. was used to measure spatial heterogeneity of blood flow in

tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at 1 and 6 h after treatment and a very large decrease in tumor blood flow, which-by 6 h-was reduced approx. 100-fold. The spleen was the most affected normal tissue with a 7-fold reduction in blood flow at 6 h. Calcns. of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quant. autoradiog. showed that CA-4-P increased the spatial heterogeneity in tumor blood flow. The drug affected peripheral tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the **nitric oxide synthase inhibitor**, N ω -nitro-L-arginine Me ester, potentiated the effect of CA-4-P in tumor tissue. The combination increased tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in tumor vascular resistance could also be obtained in isolated tumor perfusions using a cell-free perfusate, although the changes were much less than those observed in vivo. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and combretastatin A-4 (CA-4) was more efficient in tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a tumor vascular-targeting agent.

IT 117048-59-6, Combretastatin A-4 168555-66-6


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(combretastatin A-4 phosphate as a tumor vascular-targeting agent)

RN 117048-59-6 CAPLUS

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 168555-66-6 CAPLUS

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.

09/890,990



● 2 Na

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:07:10 ON 04 AUG 2004)

FILE 'REGISTRY' ENTERED AT 15:07:22 ON 04 AUG 2004

L1 STRUCTURE UPLOADED

L2 22 S L1

L3 2298 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:08:13 ON 04 AUG 2004

L4 1521 S L3

L5 3172 S NITRIC OXIDE SYNTHASE INHIBITOR?

L6 186 S NITRIC OXIDE SYNTHESIS INHIBITOR?


L7 3342 S L5 OR L6

L8 3 S L4 AND L7

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 MeO, EtO, n-PrO, i-PrO, n-BuO, i-BuO, s-BuO, t-BuO

G2 H, CN

Structure attributes must be viewed using STN Express query preparation.

09/890,990

=>